ArticleEuropean urology open science2026
PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED).
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Tumor volume and prostate-specific antigen (PSA) response (PSAr) are among the most relevant clinical prognostic factors in metastatic hormone-sensitive prostate cancer (mHSPC). However, their comparative prognostic performance has not been evaluated. We aimed to compare the prognostic value of tumor volume and 6-mo PSAr for progression and mortality in patients treated with doublet therapy. Recent data suggest that patients with high-volume (HV) disease achieving a PSAr may experience better outcomes than those with low-volume (LV) but poor PSAr. Methods: Multicenter retrospective study of patients with mHSPC who were treated with doublet therapy between 2017 and 2025. PSAr at 6 mo was categorized as complete response (CR; PSA ≤0.2 ng/ml) or non-response (NR; PSA >0.2 ng/ml). Outcomes included progression-free survival and overall survival. Prognostic performance was assessed using Kaplan-Meier survival estimates and multivariable Cox regression. Results and limitations: A total of 777 patients were included (median age 72 yr [p25-p75: 66-77 yr], of whom 47% had HV disease. The overall median follow-up for the entire cohort was 29 mo (p25-p75: 11-42 mo), whereas among patients without events, the median follow-up was 25 mo (p25-p75: 15-37 mo). The NR/HV group had the highest progression rate ( Conclusions and clinical implications: PSAr at 6 mo is a robust prognostic marker in patients with mHSPC treated with doublet therapy. Failure to achieve an early PSAr was associated with a higher mortality risk than high tumor burden alone. Integrating PSAr with tumor volume improves prognostic discrimination. However, given that the aim of this study is not to inform treatment decisions, these findings do not have direct clinical implications and should not be used to guide management. Instead, they may serve as a basis for future research aimed at refining prognostic stratification in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.